Enhancement of radiosensitivity and the potential mechanism on human esophageal carcinoma cells by tetrandrine

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 4, 2011, Pages 437-442

  Yu, Jingping ^a,b   Liu, Fenju ^a   Sun, Meiling ^a   Sun, Zhiqiang ^b   Sun, Suping ^b  

^a SOOCHOW UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

esophageal carcinoma; mechanism; radiosensitivity; TE1 cells; tetrandrine

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN B1; RADIOSENSITIZING AGENT; TETRANDRINE;

ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLONY FORMING CELL; CYTOTOXICITY; DRUG EFFECT; ESOPHAGUS CARCINOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZYLISOQUINOLINES; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYCLIN B1; ESOPHAGEAL NEOPLASMS; HUMANS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 80051742869     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.0964     Document Type: Article

References (29)

1. Yamada S, Takai Y, Nemoto K, et al. Low-dose rate telecobalt therapy as a boost against esophageal carcinomas. Cancer 1992;69:1099.
2. Smalley SR, Gunderson LL, Reddy EK, et al. Radiotherapy alone in esophageal carcinoma: Current management and future direction, adjuvant, curative and palliative approaches. Semin Oncol 1994;21:467.
3. Ruhstaller T, Templeton A, Ribi K, et al. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: A prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie 2010;33:222.
4. Gao XS, Qiao XY, Yang XR, et al. Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma. Oncol Rep 2002;9: 767.
5. Zhao KL, Shi XH, Jiang GL, et al. Late-course accelerated hyperfractionated radiotherapy for localized esophageal carcinoma. Int J Radiat Oncol Biol Phys 2004;60:123.
6. Sun SP, Liu YZ, Ye T, et al. Randomized clinical trial on seven-day-per-week continuous accelerated irradiation (CAIR) for patients with esophageal carcinoma. Preliminary report on tumour response and acute toxicity. World J Gastroenterol 2006;12:7047.
7. Yin MF, Lian LH, Piao DM, et al. Tetrandrine stimulates the apoptosis of hepatic stellate cells and ameliorates development of fibrosis in a thioacetamide rat model. World J Gastroenterol 2007;13:1214.
8. Hsu JH, Wu YC, Liou SS, et al. Mediation of endogenous beta-endorphin by tetrandrine to lower plasma glucose in streptozotocin-induced diabetic rats. ECAM 2004;1:193.
9. Qian JQ. Cardiovascular pharmacological effects of bisbenzy lisoquinoline alkaloid derivatives. Acta Pharmacol Sin 2002;23:1086.
10. Jang BC, Lim KJ, Paik JH, et al. Tetrandrine induced apoptosis is mediated by activation of caspases and PKC-delta in U937 cells. Biochem Pharmacol 2004;67:1819.
11. Park PH, Nan JX, Park EJ, et al. Effect of tetrandrine on experimental hepatic fibrosis induced by bile duct ligation and scission in rats. Pharmacol Toxicol 2000;87:261.
12. Lai JH. Immunomodulatory effects and mechanisms of plant alkaloid tetrandrine in autoimmune diseases. Acta Pharmacol Sin 2002;23:1093.
13. Pang L, Hoult JR. Cytotoxicity to macrophages of tetrandrine, an antisilicosis alkaloid, accompanied by an overproduction of prostaglandins. Biochem Pharmacol 1997;53: 773.
14. Liu Q, Guntuku S, Cui XS, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448.
15. Wang G, Lemos JR, Iadecola C. Herbal alkaloid tetrandrine: From an ion channel blocker to inhibitor of tumor proliferation. Trends Pharmacol Sci 2004;25:120.
16. Xu WL, Shen HL, Ao ZF, et al. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk Res 2006;30:407.
17. Fu LW, Zhang YM, Liang YJ, et al. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer 2002;38:418.
18. Kuo PL, Lin CC. Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells. Life Sci 2003;73:243.
19. Lai YL, Chen YJ, Wu TY, et al. Induction of apoptosis in human leukemic U937 cells by tetrandrine. Anticancer Drugs 1998;9:77.
20. Lee JH, Kang GH, Kim KC, et al. Tetrandrine induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells. Int J Oncol 2002;21:1239.
21. Sun X, Xu R, Deng Y, et al. Effects of tetrandrine on apoptosis and radiosensitivity of nasopharyngeal carcinoma cell line CNE. Acta Biochim Biophys Sin 2007;39:869.
22. Chen Y, Chen JC, Tseng SH. Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats. Int J Cancer 2009;124:2260.
23. Hsu YC, Chiu YT, Cheng CC, et al. Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis. J Gastroenterol Hepatology 2007;22:99.
24. Oh SH, Lee BH. Induction of apoptosis in human hepatoblastoma cells by tetrandrine via caspase-dependent Bid cleavage and cytochrome c release. Biochem Pharmacol 2003;66:725.
25. Chen YJ. Potential role of tetrandrine in cancer therapy. Acta Pharmacol Sin 2002;23:1102.
26. Jin Q, Kang C, Soh Y, et al. Tetrandrine cytotoxicity and its dual effect on oxidative stress-induced apoptosis through modulating cellular redox states in Neuro 2a mouse neuroblastoma cells. Life Sci 2002;71:2053.
27. Chen Y, Chen JC, Teng SH. Effects of tetrandrine plus radiation on neuroblastoma cells. Anticancer Res 2009;29: 3163.
28. Chang KH, Chen ML, Chen HC, et al. Enhancement of radiosensitivity in human glioblastoma U138MG cells by tetrandrine. Neoplasma 1999;46:196.
29. Zhao YZ, Kim JY, Park EJ, et al. Tetrandrine induces apo- ptosis in hepatic stellate cells. Phytother Res 2004;18:306.